On January 8, 2023 Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company, reported preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022 (Press release, Akoya Biosciences, JAN 8, 2023, View Source [SID1234626024]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Akoya reported the following preliminary financial results for the fourth quarter and full year 2022, which remain subject to quarter end closing adjustments:

Revenue for the fourth quarter of 2022 is expected to be between $20.7 million and $21.2 million, as compared to $16.2 million for the corresponding quarter of last year
For the fiscal year of 2022, revenue is expected to be between $74.3 million and $74.8 million, as compared to $54.9 million for fiscal year 2021
"The fourth quarter of 2022 was another record quarter for Akoya, demonstrating our continued business momentum and commercial execution," said Brian McKelligon, Chief Executive Officer. "In 2022, we delivered strong financial performance and saw growing adoption of our spatial biology platforms across the discovery, translational, and clinical markets."

A link to a webcast replay of Akoya’s 2nd annual Spatial Day, which took place virtually on December 15, 2022, can be found below:

Akoya Biosciences Spatial Day 2022 | Akoya

The financial results in this press release reflect expectations based on currently available information. The company has yet to complete its quarter end closing and actual results are therefore subject to change.